Moderna: COVID vaccine for B.1.351 SARS-CoV-2 variant enters early stage trial
by Press Release from Outbreak News Today on (#5G190)
An investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate's safety and immunogenicity in adult volunteers. The vaccine, known as mRNA-1273.351, was developed by the biotechnology company ModernaTX, Inc., based in Cambridge, Massachusetts. The trial is led and [...]
The post Moderna: COVID vaccine for B.1.351 SARS-CoV-2 variant enters early stage trial appeared first on Outbreak News Today.